Dong-A Enrolls GSK Korea General Manager On Board Of Directors; GSK Says Move Will Strengthen Alliance, Not Influence
This article was originally published in PharmAsia News
SEOUL - Korea's leading pharma Dong-A Pharmaceutical Co. Ltd. placed GlaxoSmithKline PLC's Korea General Manager Kim Jin-ho on its nine-member board of directors in a follow-up action to GSK's acquisition of a 9.9% stake in Dong-A in May 2010
You may also be interested in...
Otsuka is among six MNCs, including Pfizer, AstraZeneca, Novartis, Sanofi and Merck that have inked large R&D deals with Korea’s Ministry of Health.
Dong-A Pharmaceutical is pushing to create a favorable environment for a temporary shareholder meeting on Jan. 28, though the third-largest shareholder, the National Pension Service, is opposed to a proposal to float a holding company.
Instead of providing rebates through its own sales representatives, Korea’s largest domestic company tried to sidestep anti-rebate laws using marketing and distribution agencies to provide rebates to hospitals and doctors.